 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Feb 01, 2011 |
| Title |
Gene expression data of non-leukemic individuals before and during in-vivo glucocorticoid treatment |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Article title: Expression, regulation and function of phosphofructo-kinase/fructose-biphosphatases (PFKFBs) in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia cells.
Glucocorticoids (GCs) cause apoptosis and cell cycle arrest in lymphoid cells and constitute a central component in the therapy of lymphoid malignancies, most notably childhood acute lymphoblastic leukemia (ALL). PFKFB2 (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-2), a kinase controlling glucose metabolism, was identified by us previously as a GC response gene in expression profiling analyses performed in children with ALL during initial systemic GC mono-therapy. Since deregulation of glucose metabolism has been implicated in apoptosis induction, this gene and its relatives PFKFB1, 3, and 4 were further analyzed. Expression analyses in additional ALL children, non-leukemic individuals and leukemic cell lines confirmed frequent PFKFB2 induction by GC in most systems sensitive to GC-induced apoptosis, particularly in T-ALL cells. The 3 other family members, in contrast, were not or weakly expressed (PFKFB1 and 4) or not induced by GC (PFKFB3). Conditional PFKFB2 over-expression in the CCRF-CEM T-ALL in vitro model revealed that its 2 splice variants (15A and 15B) did not have any detectable effect on survival or cell cycle progression. Moreover, neither PFKFB2 splice variant significantly affected sensitivity to, or kinetics of, GC-induced apoptosis. Our data suggest that, at least in the model system investigated, PFKFB2 is not an essential upstream regulator of the anti-leukemic effects of GC.
|
| |
|
| Overall design |
Gene expression profiles of 4 non-leukemic individuals (1 healthy and 3 with epilepsy) were generated from mononuclear cells isolated from peripheral blood samples before, and after 2, 6, and 24 hours of in-vivo glucocorticoid treatment.
|
| |
|
| Contributor(s) |
Carlet M, Janjetovic K, Rainer J, Schmidt S, Panzer R, Mann G, Prelog M, Meisted B, Ploner C, Kofler R |
| Citation(s) |
21092265 |
| |
| Submission date |
Jul 06, 2010 |
| Last update date |
Mar 25, 2019 |
| Contact name |
Johannes Rainer |
| E-mail(s) |
johannes.rainer@eurac.edu
|
| Organization name |
Eurac Researc
|
| Department |
Institute for Biomedicine
|
| Lab |
Biomedical Informatics
|
| Street address |
Via A. Volta 21
|
| City |
Bolzano |
| ZIP/Postal code |
39100 |
| Country |
Italy |
| |
|
| Platforms (1) |
| GPL570 |
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array |
|
| Samples (16)
|
| GSM563241 |
Epilepsy patient E3, untreated sample |
| GSM563242 |
Epilepsy patient E3, 2 hours GC treatment |
| GSM563243 |
Epilepsy patient E3, 6 hours GC treatment |
| GSM563244 |
Epilepsy patient E3, 24 hours GC treatment |
| GSM563245 |
Epilepsy patient E4, untreated sample |
| GSM563246 |
Epilepsy patient E4, 2 hours GC treatment |
| GSM563247 |
Epilepsy patient E4, 6 hours GC treatment |
| GSM563248 |
Epilepsy patient E4, 24 hours GC treatment |
| GSM563249 |
Epilepsy patient E5, untreated sample |
| GSM563250 |
Epilepsy patient E5, 2 hours GC treatment |
| GSM563251 |
Epilepsy patient E5, 6 hours GC treatment |
| GSM563252 |
Epilepsy patient E5, 24 hours GC treatment |
| GSM563253 |
Healthy donor, untreated sample |
| GSM563254 |
Healthy donor, 2 hours GC treatment |
| GSM563255 |
Healthy donor, 6 hours GC treatment |
| GSM563256 |
Healthy donor, 24 hours GC treatment |
|
| Relations |
| BioProject |
PRJNA128087 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE22779_RAW.tar |
76.2 Mb |
(http)(custom) |
TAR (of CEL) |
| Processed data included within Sample table |
|
|
|
|
 |
Less...
More...